Sodium zirconium cyclosilicate

Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K+ in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD)[1][2].

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

Sodium zirconium cyclosilicate (ZS-9) is an inorganic cation exchange crystalline compound that has a high capacity to selectively entrap monovalent cations, specifically excess K+ and ammonium ions. Sodium zirconium cyclosilicate has the exchange capacities for the divalent ions Ca2+ and Mg2+ are below 0.05 mEq/g, and a >25-fold selectivity for K+ over either Ca2+ or Mg2+[1].

Sodium zirconium cyclosilicate (ZS-9; 2-6 g/kg; p.o.; daily, for 5 d) is a recovery in feces of Sprague-Dawley rats and can efficient uptake and removal of potassium ions[2]. Animal Model: Sprague-Dawley rats[2] Dosage: 2, 4, and 6 g/kg Administration: Oral administration; daily, for 5 days Result: Had 99% fecal recovery in rats. Uptake and removal of potassium ions in a dose-dependent manner.